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A B S T R A C T
Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients
with MDS have a normal karyotype. Usually, 20–25 normal metaphases (nMP) are considered to be optimal to
exclude small abnormal clones which might be associated with poor prognosis. This study evaluated the impact
of examining a suboptimal number of metaphases in patients recruited to the EUMDS Registry with low and
intermediate-1 risk according to IPSS. Only 179/1049 (17%) of patients with a normal karyotype had a sub-
optimal number of nMP, deﬁned as less than 20 metaphases analyzed. The outcome (overall survival and
progression-free survival) of patients with suboptimal nMP was not inferior to those with higher numbers of
analyzed MP both in univariate and multivariate analyses. For patients with an abnormal karyotype, 224/649
(35%) had a suboptimal number of MP assessed, but this did not impact on outcome. For patients with a normal
karyotype and suboptimal numbers of analyzable metaphases standard evaluation might be acceptable for
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general practice, but we recommend additional FISH-analyses or molecular techniques, especially in candidates
for intensive interventions.
1. Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of
clonal myeloid disorders characterized by peripheral blood cytopenias
and increased risk of transformation to acute myelogenous leukemia
(AML) [1]. Classical karyotype analyses detect clonal chromosome
abnormalities in about 50% of patients with MDS [2]. The karyotype is
one of the strongest prognostic parameters in the currently applied
prognostic models, including the revised International Prognostic
Scoring System (IPSS-R) [3]. In general, the aim is to analyze 20 or
more metaphases (MP) before a karyotype is considered to lack speciﬁc
clonal abnormalities. A lower number of MP analyzed (< 20) is asso-
ciated with a higher chance of missing small clones [2]. The prognostic
relevance of these smaller clones remains to be elucidated in lower-risk
MDS [4].
The primary aim of the present study was to assess whether the
number of MP examined in patients with normal karyotype provide any
additional prognostic information about overall survival (OS) and
progression-free survival (PFS) in patients with lower-risk MDS parti-
cipating in the European MDS Registry Study [5]. The secondary aim
was to assess the impact of the number of analyzed metaphases on
outcome in patients with an abnormal karyotype. To the best of our
knowledge, this is the ﬁrst prospective study in this ﬁeld. We hy-
pothesized that a higher number of analyzed nMP does have a positive
impact on survival in patients with lower-risk MDS.
2. Design and methods
2.1. Eligibility
Patients were eligible for inclusion if they were newly diagnosed
with MDS according to the WHO 2001 classiﬁcation [6] and had a low
or intermediate-1 risk score according to the IPSS [7]. Patients with
post-cytotoxic MDS have been excluded from this Registry. The ethics
committees of all participating countries and centers have approved the
EUMDS registry (trial number NCT00600860). Patient-speciﬁc (in-
cluding bone marrow morphology, histology and cytogenetics), inter-
vention and outcome data were collected at baseline and at each 6-
monthly out-patient follow-up visit for the routine clinical care of
patients with MDS. All subjects were prospectively followed until death,
progression to higher-risk MDS or leukemia, loss to follow-up or with-
drawal of informed consent.
2.2. Assignment of IPSS(-R) score
Both the IPSS cytogenetic score and the IPSS-R cytogenetic score
were determined from the diagnostic cytogenetic reports at registra-
tion. The local investigator assigned the IPSS cytogenetic scores. The
IPSS-R cytogenetic scores were retrospectively assigned by one of the
investigators of the EUMDS registry and veriﬁed by an independent
expert of the international IPSS working group (D. Haase). IPSS and
IPSS-R scores were calculated and the IPSS-R cytogenetic risk category
of patients with only nMP was assigned as good-risk. In these cases no
abnormal MP were reported. Patients with abnormal MP were cate-
gorized to the IPSS-R cytogenetic risk score: very good, good, inter-
mediate, poor and very poor risk category [8].
2.3. Statistical analysis
Standard descriptive techniques were used to assess the distribution
of baseline patient characteristics including chi squared test and
Wilcoxon rank sum test. Overall survival (OS) was deﬁned as the time
from date of diagnosis to death, or for subjects still alive at the date of
the last follow-up visit. Time to disease progression (TDP) was mea-
sured from date of diagnosis to date of disease progression to either
higher-risk MDS or acute leukemia. Patients without disease progres-
sion were censored at date of death or date of last follow-up visit.
Standard methods were used to assess time to event, namely Cox pro-
portional hazards regression models and Kaplan–Meier survival curves.
Hazard ratios (HR) and 95% conﬁdence intervals (95% CI) are reported
for univariate analyses, unadjusted and adjusted for sex and age at di-
agnosis. All analyses were undertaken in Stata 14 (StataCorp, College
Station, TX).
3. Results
In total 2196 patients were registered to the study between 1st April
2008 to 31st March 2017 and patients were followed-up to the 1st June
Table 1
Number of metaphases by age at diagnosis and cytopenias for subjects with a normal karyotype only or an abnormal karyotype.
Metaphase category (n) N (%) Median age
years (range)
Median (25–75 percentile)
Hemoglobin (g/dL) Platelets (109/L) Absolute Neutrophils Count (109/L)
Normal karyotype
Total 1225 (100) 73 (18–93) 10.3 (9.2–11.6) 171 (96–263) 2.4 (1.3–3.8)
1–9 42 (3.4) 72 (47–89) 10.3 (9.2–11.6) 179 (88–264) 2.6 (1.2–4.1)
10–19 137 (11.2) 72 (21–90) 9.8 (8.8–11.4) 169 (97–263) 2.4 (1.4–3.7)
20–24 634 (51.8) 74 (21–93) 10.2 (9.1–11.4) 173 (96–270) 2.4 (1.3–3.8)
25–29 164 (13.4) 73 (42–93) 10.6 (9.7–11.7) 160.5 (94–270) 2.2 (1.2–3.6)
30+ 72 (5.9) 74 (57–90) 10.8 (9.8–12.1) 181.5 (99–253) 2.4 (1.4–4.1)
Not recorded 176 (14.4) 74 (18–93) 10.6 (9.4–11.8) 169 (101–257) 2.4 (1.4–3.9)
Abnormal karyotype
Total 774 (100) 75 (21–97) 10 (9–11.1) 177.5 (103–283) 2.4 (1.4–3.8)
1–9 44 (5.7) 70 (39–93) 9.8 (8.9–10.9) 162 (67.5–236) 1.8 (1.2–3.3)
10–19 180 (23.3) 75 (21–93) 10 (9–11.1) 197 (114–296) 2.2 (1.4–3.5)
20–24 276 (35.7) 77 (33–93) 9.9 (9–11.1) 168 (103–290) 2.6 (1.5–4)
25–29 104 (13.4) 74 (34–89) 10.2 (9.1–11.4) 181 (106–292) 2.8 (1.5–4.4)
30+ 45 (5.8) 77 (27–91) 10.3 (9–11.2) 189 (98–258) 2.2 (1.4–3.7)
Not recorded 125 (16.1) 73 (46–97) 9.7 (8.5–10.9) 172 (102–275) 2.1 (1.4–3.6)
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2017. The majority of patients had conventional cytogenetics per-
formed (95%) and 1999 had a karyotype recorded. Sixty-one percent
had a normal karyotype (1225/1999) at diagnosis and 39% an ab-
normal karyotype (774/1999). Patients were subdivided into six cate-
gories based on the number of reported MP (Table 1). The median
number of MP examined was 20 for patients with normal and abnormal
karyotypes, however, the distributions were very diﬀerent as can be
seen in Fig. 1 (p= .01). Whilst some patients with an abnormal kar-
yotype had over 40 MP assessed, 35% had less than 20 MP assessed
(suboptimal), this is in contrast to those with a normal karyotype where
only 17.1% had less than 20 MP assessed (p < 0.0001). Patients with
an abnormal karyotype were, on average, older (75 vs 73 years,
p= .03), and in terms of cytopenias they lower hemoglobin values than
those with a normal karyotype (p < .0001). However, there were no
diﬀerences in hemoglobin, platelets or neutrophil counts by number of
metaphases examined (Table 1).
Table 2 shows the number of normal MP were evenly distributed
within the various categories with the exception of the participating
countries. The median number of analyzed MP was signiﬁcantly higher
(p < .0001) in the two Scandinavian countries compared to the
number of MP in Israel, Italy, Serbia, Croatia and Romania. As ex-
pected, there were diﬀerences between the normal and abnormal kar-
yotypes groups in terms of WHO diagnosis and IPSS-R score; patients
with an abnormal karyotype were more likely to have been transfused
at diagnosis compared to those with a normal karyotype.
3.1. Overall survival and progression-free survival
Median follow-up was 2.1 years (range of 0.1–8.7 years) and 33%
(669 of 1999) of patients had died during the observation period;
median survival for patients with a normal karyotype was 5.2 years
(95% Conﬁdence Intervals (95% CI): 3.3–4.5) and abnormal karyotype
(4.0 years (95% CI: 4.0 (4.8–5.9) log rank test= 15.63, p= .0001. The
univariate overall survival (Fig. 2A and B) and progression-free survival
estimates, as depicted in Fig. 3A and B, showed a similar outcome in the
six categories throughout the whole observation period.
Multivariate analyses were performed to adjust for the various re-
levant prognostic components: age at diagnosis, MDS WHO category,
blast count, hemoglobin levels, platelets and neutrophil count, RBCT-
dependency (> 1 unit/month for 6 months) and country. IPSS-R cyto-
genetic risk category was also included in the model in patients with an
abnormal karyotype. The largest category of MP (20–24MP) was used
as the reference category. The number of MP, analyzed both as a con-
tinuous variable or as a categorical variable did not signiﬁcantly in-
ﬂuence survival nor progression-free survival. The group with MP not
recorded in the database were included in all analyses (Table 3 and
Figs. 2 and 3).
Fig. 1. Distribution of number metaphases by abnormal vs normal karyotype.
The p-value (=.01) shows a signiﬁcant diﬀerence in median number of analyzed meta-
phases in the normal and abnormal karyotype groups. The aim in assigning an abnormal
karyotype is not to analyze 20 or more metaphases (MP) compared to a normal karyotype
where the aim is to analyze 20 or more metaphases (MP).
Table 2
Demographic parameters and impact on median number of metaphases.
Category Normal karyotype Abnormal karyotype
No. of
patients
No. of nMP
Median (range)
No. of
patients
No. of MP
Median (range)
Total 1049 (100) 20 (1–42) 649 (100) 20 (1–60)
Age
< 60 years 130 (12.4) 20 (4–34) 50 (7.7) 20 (4–47)
60–70 247 (23.5) 20 (2–42) 138 (21.3) 20 (1–52)
70+ 672 (64.1) 20 (1–38) 461 (71) 20 (1–60)
WHO-diagnosis
RA 164 (15.6) 20 (3–42) 101 (15.6) 20 (6–52)
RARS 190 (18.1) 20 (1–34) 78 (12) 20 (9–34)
RCMD 429 (40.9) 20 (2–38) 245 (37.8) 20 (1–60)
RCMD-RS 73 (7) 20 (3–38) 33 (5.1) 21 (7–40)
RAEB-1 143 (13.6) 20 (2–35) 60 (9.2) 20 (1–47)
RAEB-2 6 (0.6) 20 (10–23) – –
MDS-U 44 (4.2) 20 (8–34) 29 (4.5) 14 (1–30)
5q-Syndrome – 103 (15.9) 20 (3–37)
Country
Austria 65 (6.2) 22 (4–34) 41 (6.3) 20 (1–31)
Croatia 2 (0.2) 20 (20–20) 5 (0.8) 16 (7–21)
Czech Republic 50 (4.8) 22 (2–25) 42 (6.5) 22 (8–40)
Denmark 36 (3.4) 25 (10–26) 20 (3.1) 25 (25–28)
France 291 (27.7) 20 (8–36) 162 (25) 21 (4–49)
Germany 27 (2.6) 22 (2–29) 21 (3.2) 22 (5–34)
Greece 70 (6.7) 20 (2–29) 58 (8.9) 20 (5–52)
Israel 60 (5.7) 10 (3–21) 37 (5.7) 10 (2–28)
Italy 40 (3.8) 17 (1–25) 22 (3.4) 14 (3–25)
Netherlands 45 (4.3) 20 (10–20) 22 (3.4) 10.5 (10–30)
Poland 29 (2.8) 22 (5–27) 26 (4) 21 (18–30)
Portugal 17 (1.6) 20 (20–30) 16 (2.5) 10 (6–29)
Romania 12 (1.1) 15 (8–24) 9 (1.4) 16 (9–22)
Serbia 8 (0.8) 15 (1–15) 8 (1.2) 30 (5–30)
Spain 80 (7.6) 20 (5–42) 37 (5.7) 20 (3–47)
Sweden 54 (5.1) 26 (20–38) 38 (5.9) 25 (20–30)
United Kingdom 163 (15.5) 20 (3–30) 85 (13.1) 10 (1–60)
IPSS-R* Cytogenetics
Very Good – – 156 (24.0) 20 (1–60)
Good 1049 (100) 20 (1–42) 250 (38.5) 20 (1–39)
Intermediate – – 206 (31.7) 20 (1–49)
Poor – – 21 (3.2) 20 (1–60)
Very Poor – – 16 (2.5) 20 (4–28)
IPSS-R* Overall 986 (100) 20 (1–42) 610 (100) 20.0 (1–60)
Very low 309 (31.3) 20 (1–42) 166 (27.2) 20 (2–39)
Low 480 (48.7) 20 (1–38) 245 (40.2) 20 (1–60)
Intermediate 161 (16.3) 20 (2–35) 152 (24.9) 20 (1–40)
High 35 (3.5) 20 (10–32) 42 (6.9) 20 (1–30)
Very high 1 (0.1) 20 5 (0.8) 20 (5–20)
Transfused at registration
No 761 (72.5) 20 (1–35) 427 (65.8) 20 (1–60)
Yes 288 (27.5) 20 (1–42) 222 (34.2) 20 (1–39)
Transfused> 1 unit/month
No 886 (84.5) 20 (1–42) 504 (77.7) 20.0 (1–60)
Yes 163 (15.5) 20 (2–38) 145 (22.3) 20.0 (1–39)
*IPSS-R: Revised International Prognostic Scoring System.
L. de Swart et al. /HXNHPLD5HVHDUFK²

4. Discussion
The analyses of this study were focused on the impact of analyzable
metaphases in patients with a normal karyotype on outcome, including
estimated overall survival and progression-free survival. Our recently
published study on the ﬁrst 1000 patients within the EUMDS registry
conﬁrmed established prognostic factors, such as age, gender and
World Health Organization 2001 classiﬁcation [5] in addition, with low
health-related quality of life (EQ-5D visual analogue scale score) and a
high co-morbidity index predicted poor outcome. The IPSS-R was su-
perior to the original IPSS for predicting both disease progression and
survival [5]. We identiﬁed 1225 patients with normal conventional
Fig. 2. Overall Survival.
Overall survival from date of diagnosis by the six analyzed categories based on the number of reported metaphases; normal karyotype 2A, and abnormal karyotype 2B. The columns under
the ﬁgures represent the number of patients in each of the categories at that speciﬁc time point.
Fig. 3. Progression-free survival.
Progression-free survival from date of diagnosis by the six analyzed categories based on the number of reported metaphases; normal karyotype 2A, and abnormal karyotype 2B. The
columns under the ﬁgures represent the number of patients in each of the categories at that speciﬁc time point.
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karyotype in the EUMDS Registry, representing 61% of this lower-risk
MDS patient population. The great majority of patients with normal
karyotype had 20 or more MP analyzed, while 14% of the patients were
registered with a normal karyotype, based on less than 20 analyzed MP.
Estimated overall survival as well as the estimated progression-free
survival of the patients with a normal karyotype and a suboptimal
number of analyzed MP (<20) was not inferior when compared with
20 or more analyzed MP. In our study, we found a complete absence of
a trend towards an impaired prognostic risk when comparing the
varying cohorts. This is not surprising, since the chance of missing a
small abnormal clone increases by 25% if only 5 normal MP have been
analyzed and between 10 and 15% in patients with 10–15 nMP ana-
lyzed [2]. This means that the majority of patients with a suboptimal
number of analyzed MP (<20) are expected to have a conventionally
normal karyotype associated with a low risk MDS. In contrast, the size
of abnormal clones may play a role in the prognosis [9]. In the study by
Mallo et al. the outcome of patients with abnormal clones< 100%,
assessed by FISH, was better when compared to patients with 100%
abnormal clones [9]. Unfortunately, the impact of smaller clone sizes
was not assessed in that study, similar to a large important study,
performed by Schanz, et al. [10]. A study of 101 MDS patients with
normal karyotype revealed small clones (ranging 15% to 32%) using
FISH techniques in 18 patients [4]. FISH abnormalities were predictive
for worse prognosis, but the majority of these 18 patients had higher-
risk MDS and all three patients with refractory anemia were surviving
at time of evaluation. It is also possible to apply FISH on circulating
CD34-positive cells, in order to avoid another BM aspiration to obtain
suﬃcient material for standard banding techniques [11].
Additionally, we analyzed the patients with abnormal karyotypes.
As expected the number of analyzed metaphases is lower in this group
of patients because the deﬁnition of clonality in patients with abnormal
karyotype requires a lower number of analyzed metaphases. Also in this
group of patients the number of analyzed metaphases does not inﬂu-
ence the outcome after adjustment for relevant variables.
Currently, it is possible to detect MDS-speciﬁc mutations in more
than 90% of patients with MDS [12]. These mutations will allow a
better prognostication of all MDS cases with normal karyotype.
Therefore, molecular testing should be seriously considered in all ﬁt
patients with MDS who are candidates for allogeneic stem cell trans-
plantation or patients in investigational studies, in absence of poor-risk
cytogenetic characteristics, as is the case in all patients with MDS,
characterized by normal karyotype [13].
In summary: patients with lower-risk MDS with a normal karyotype
and suboptimal numbers of analyzable metaphases (< 20) have a si-
milar outcome when compared to patients with optimal numbers of
analyzed metaphases (≥20). However, it should be a general aim to
reach at least a complete analysis of 20 metaphases to be able to ex-
clude clonal cytogenetic abnormalities, especially in patients who are
eligible for intensive interventions. If this is not possible, we re-
commend to use complementary FISH-analyses covering the most fre-
quent cytogenetic changes such as del(5q), monosomy 7/del(7q),
trisomy 8, del(17p)/loss of TP53-alleles and del(20q), or additional or
molecular techniques [13].
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HR (95% CI) Adjusted HR
(95% CI)a
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(95% CI)a
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(0.42–1.61)
1.06
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(0.87–1.65)
a Age, transfused, WHO diagnosis, platelets counts, neutrophil counts, hemoglobin
levels, country.
b Age, transfused, WHO diagnosis, platelets counts, neutrophil counts, hemoglobin
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